DNMT3A and acute myeloid leukemia: More precisely, age, DNMT3A (R882 variant), IDH1 and MRGs have been identified as unfavorable factors for EFS, while mutations in the cohesin complex and treatment with gemtuzumab ozogamicin (GO) have been described as favorable EFS factors in NPM1-mutated AML [101].